RZLT — Rezolute, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1509261 ·
Last close
$4.01
Market Cap
$388.37M
52W High
$11.16
52W Low
$1.07
ADV30
1,679,454
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -19,385,000 | -18,487,000 | 96,010,000 | 8,150,000 | 10,062,000 |
| Jun 2026 | 0 | — | -21,562,000 | -20,491,000 | 112,849,000 | 10,615,000 | 12,162,000 |
| Mar 2026 | 0 | — | -17,366,000 | -16,171,000 | 125,459,000 | 11,236,000 | 8,625,000 |
| Dec 2025 | 0 | — | -24,221,000 | -22,774,000 | 138,629,000 | 11,944,000 | 10,631,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-64,635,000
Investing CF
$-21,098,000
Financing CF
$2,241,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.76
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-481,442,000
Inventory
—
Receivables
—
ST Investments
$97,186,000
EBIT TTM
$-82,966,000
Pretax Income TTM
$-77,586,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | -82,966,000 | -77,586,000 | 112,849,000 | 12,162,000 | 100,687,000 | -64,635,000 |
| Jun 2025 | 0 | -79,894,000 | -74,412,000 | 175,490,000 | 13,363,000 | 162,127,000 | -69,075,000 |
| Jun 2024 | 0 | -70,423,000 | -68,459,000 | 132,737,000 | 11,734,000 | 121,003,000 | -57,368,000 |
| Jun 2023 | 0 | -55,990,000 | -51,787,000 | 123,721,000 | 7,549,000 | 116,172,000 | -44,481,000 |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-77,586,000
OpCashFlow TTM
—
Assets (Latest)
$125,459,000
Forward EPS
$-0.45
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.25 · call volume: 283 · put volume: 82
Expected Move to 2026-12-18:
±$1.83
(43.06%) —
implied range
$2.42 –
$6.08
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IRD | Opus Genetics, Inc. | $391.45M | $4.05 | — |
| ELTP | ELITE PHARMACEUTICALS INC /NV/ | $397.36M | $0.37 | — |
| PTCHF | PureTech Health plc | $405.77M | $1.65 | — |
| CRMD | CorMedix Inc. | $371.44M | $4.67 | — |
| NIKA | NIKA PHARMACEUTICALS, INC | $369.14M | $0.35 | — |
News headlines (Yahoo Finance, 1h cache)
Rezolute Raises $100 Million, Advances Ersodetug Toward Commercialization
2026-11-13 17:27 · Yahoo
Rezolute Reports Phase 3 upLIFT Study Meets Primary Efficacy Endpoint in Tumor Hyperinsulinism
2026-11-13 15:50 · Yahoo
Rezolute stock rises on positive Phase 3 upLIFT trial results
2026-11-13 14:23 · Yahoo
Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
2026-11-13 11:19 · Yahoo
Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update
2026-11-05 21:05 · Yahoo
Rezolute to Participate in Upcoming Investor Conferences
2026-11-02 12:30 · Yahoo
Rezolute Gets FDA Nod For Pre-BLA Meeting Despite Phase 3 Miss — Retail Expects ‘Huge Rerating’
2026-10-05 12:58 · Yahoo
Rezolute Says FDA Recommends Pre-BLA Meeting for Congenital Hyperinsulinism Treatment
2026-10-05 12:04 · Yahoo
Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism
2026-10-05 11:00 · Yahoo
Sector Update: Healthcare Stocks Softer Late Afternoon
2026-09-09 19:49 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.